CSPC Pharmaceutical Group Limited
CSPCY
Other OTC3.81
USD
-0.08
- -
CSPC Pharmaceutical Group Limited
CSPCY
(Other OTC)
Recent
price
3.81
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- CSPC Pharmaceutical Group Limited operates as a prominent investment holding entity, driving the discovery, development, production, and distribution of pharmaceutical products across mainland China, various Asian territories, the Americas, Europe, and globally. The company organizes its business activities through distinct segments encompassing finished drugs, bulk ingredients, and functional foods alongside other related ventures. Its comprehensive portfolio of finished medications addresses a wide array of therapeutic areas, including neurological conditions, oncology, anti-infective treatments, and cardiovascular disorders. Key innovative offerings include NBP formulations, presented as soft capsules and injections for addressing acute ischemic stroke, and Oulaining capsules and lyophilized powders, targeted at mild to moderate cognitive and mental impairments. Enxi is available for managing adult idiopathic Parkinson's disease, while Duomeisu serves in the treatment of lymphomas, multiple myelomas, ovarian and breast cancers, and other malignant tumors. Further, Jinyouli aids in the prevention of chemotherapy-induced leucopenia and infection, with Keaili specifically developed for breast cancer. The company also provides Xuanning for hypertension, Encun to mitigate atherosclerotic thrombosis events, and a suite of anti-infectives like Shuluoke, Nuomoling, Weihong, and Xinweihong. For diabetes management, Linmeixin and Shuanglexin are available, alongside Gubang and Gubangjia for postmenopausal osteoporosis. Gaoshunsong offers relief for inflammatory and degenerative joint conditions such as arthritis, osteoarthritis, ankylosing spondylitis, as well as various pains including dysmenorrhea, toothache, and post-operative discomfort. Additionally, Debixin targets ulcer conditions, and Qimaite provides relief for acute and chronic pains. Beyond finished dosages, CSPC manufactures and supplies active pharmaceutical ingredients (APIs), including different forms of vitamin C, a range of antibiotics such as penicillin G potassium salt, cefazolin sodium, and azithromycin, and caffeine series products like anhydrous and crude caffeine. The functional food and other segments encompass products such as caffeine food additives, anhydrous glucose, and vitamin C buccal tablets, alongside the provision of healthcare services. The company notably invests significantly in research and development, with a strategic emphasis on innovative drugs, and has expanded its R&D footprint with bases in China and the United States. Recent pipeline advancements in 2025 include multiple clinical trial approvals in the U.S. for drugs like JMT202, SYH2070, and SYS6040, as well as China's National Medical Products Administration accepting a new drug application for Efmedaglutide Alfa Injection and approving clinical trials for SYH2056 tablets for depression treatment. CSPC Pharmaceutical Group Limited, established in 1997 through a merger of four pharmaceutical entities in Shijiazhuang, Hebei Province, China, traces its origins to 1938. Initially listed on the Hong Kong Stock Exchange in 1994 as China Pharmaceutical Group Limited, it officially adopted the name CSPC Pharmaceutical Group Limited in March 2013 and maintains its headquarters in Shijiazhuang, People's Republic of China.
AstraZeneca obesity tie-up with CSPC seen as shrewd move
CSPC Pharmaceutical Group (OTCMKTS:CSPCY) Shares Down 0.5% – Here’s What Happened